Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

Taiji Goto; Akiko Shiina; Toshiharu Yoshino; Kiyoshi Mizukami; Kazuki Hirahara; Osamu Suzuki; Yoshitaka Sogawa; Tomoko Takahashi; Tsuyoshi Mikkaichi; Naoki Nakao; Mizuki Takahashi; Masashi Hasegawa; Shigeki Sasaki

doi:10.1016/j.bmcl.2013.03.104

Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

Taiji Goto, Akiko Shiina, Toshiharu Yoshino, Kiyoshi Mizukami, Kazuki Hirahara, Osamu Suzuki, Yoshitaka Sogawa, Tomoko Takahashi, Tsuyoshi Mikkaichi, Naoki Nakao, Mizuki Takahashi, Masashi Hasegawa, Shigeki Sasaki

Chemo-Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC ₅₀ = 150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC₅₀ = 25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC₅₀ = 7.5 nM) and TNF-α production in mouse splenocytes (IC₅₀ = 9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID₅₀ = 18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand-enzyme complex.

Original language	English
Pages (from-to)	3325-3328
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	23
Issue number	11
DOIs	https://doi.org/10.1016/j.bmcl.2013.03.104
Publication status	Published - Jun 1 2013

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/j.bmcl.2013.03.104

Cite this

Goto, T., Shiina, A., Yoshino, T., Mizukami, K., Hirahara, K., Suzuki, O., Sogawa, Y., Takahashi, T., Mikkaichi, T., Nakao, N., Takahashi, M., Hasegawa, M., & Sasaki, S. (2013). Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 23(11), 3325-3328. https://doi.org/10.1016/j.bmcl.2013.03.104

Goto, T, Shiina, A, Yoshino, T, Mizukami, K, Hirahara, K, Suzuki, O, Sogawa, Y, Takahashi, T, Mikkaichi, T, Nakao, N, Takahashi, M, Hasegawa, M & Sasaki, S 2013, 'Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors', Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 11, pp. 3325-3328. https://doi.org/10.1016/j.bmcl.2013.03.104

@article{b10526d180d046848633ec56c909bb2f,

title = "Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors",

abstract = "2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC 50 = 150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50 = 25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50 = 7.5 nM) and TNF-α production in mouse splenocytes (IC50 = 9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50 = 18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand-enzyme complex.",

author = "Taiji Goto and Akiko Shiina and Toshiharu Yoshino and Kiyoshi Mizukami and Kazuki Hirahara and Osamu Suzuki and Yoshitaka Sogawa and Tomoko Takahashi and Tsuyoshi Mikkaichi and Naoki Nakao and Mizuki Takahashi and Masashi Hasegawa and Shigeki Sasaki",

year = "2013",

month = jun,

day = "1",

doi = "10.1016/j.bmcl.2013.03.104",

language = "English",

volume = "23",

pages = "3325--3328",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Limited",

number = "11",

}

TY - JOUR

T1 - Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

AU - Goto, Taiji

AU - Shiina, Akiko

AU - Yoshino, Toshiharu

AU - Mizukami, Kiyoshi

AU - Hirahara, Kazuki

AU - Suzuki, Osamu

AU - Sogawa, Yoshitaka

AU - Takahashi, Tomoko

AU - Mikkaichi, Tsuyoshi

AU - Nakao, Naoki

AU - Takahashi, Mizuki

AU - Hasegawa, Masashi

AU - Sasaki, Shigeki

PY - 2013/6/1

Y1 - 2013/6/1

N2 - 2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC 50 = 150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50 = 25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50 = 7.5 nM) and TNF-α production in mouse splenocytes (IC50 = 9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50 = 18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand-enzyme complex.

AB - 2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC 50 = 150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50 = 25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50 = 7.5 nM) and TNF-α production in mouse splenocytes (IC50 = 9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50 = 18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand-enzyme complex.

UR - http://www.scopus.com/inward/record.url?scp=84877582531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877582531&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2013.03.104

DO - 10.1016/j.bmcl.2013.03.104

M3 - Article

C2 - 23602400

AN - SCOPUS:84877582531

VL - 23

SP - 3325

EP - 3328

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 11

ER -

Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this